[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"obese\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:obese":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,49,82,105,129,152,173,197,223,244,272,301,321,347,367,392,416,443],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":48},"100620863","a-clinical-trial-to-investigate-the-safety-and-efficacy-of-mb-1-on-metabolic-health-in-overweight-and-obese-adults-100620863",false,"NCT07363148","A Clinical Trial to Investigate the Safety and Efficacy of MB-1 on Metabolic Health in Overweight and Obese Adults","A Randomized, Double-blind, Placebo-controlled, Parallel Clinical Trial to Investigate the Safety and Efficacy of MB-1 on Metabolic Health in Overweight and Obese Adults","Inclusion Criteria:\n\n1. Males \\& females aged 18-50 years, inclusive\n2. BMI of 25.0 to ≤ 34.9 kg\u002Fm²\n3. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening Or,\n\n   Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically-approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:\n   * Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)\n   * Double-barrier method\n   * Intrauterine devices\n   * Non-heterosexual lifestyle and agrees to use contraception if planning on changing to heterosexual partner(s)\n   * Vasectomy of partner at least 6 months prior to screening\n   * Abstinence and agrees to use contraception if planning on becoming sexually active during the study\n4. Stable body weight defined as a \\\u003C5% change in body weight in the three months prior to baseline as assessed by the QI\n5. Abdominal obesity: Waist circumference of \\> 94 cm (37 inches) in men and \\> 80 cm (31.5 inches) in women\n6. Willingness to complete questionnaires, records and diaries associated with the study and to complete all clinic visits\n7. Agrees to maintain current lifestyle habits (diet, medications, supplements, and sleep) as much as possible throughout the study\n8. Provided voluntary, written, informed consent to participate in the study\n9. Healthy as determined by medical history as assessed by Qualified Investigator (QI)\n\nExclusion Criteria:\n\n1. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study\n2. Allergy, sensitivity, or intolerance preventing consumption of the investigational product or placebo ingredients\n3. Gastric bypass surgery or other surgeries to induce weight loss\n4. Metal implants or other physical characteristics\u002Flimitations that may affect DEXA scan results as assessed by the QI\n5. Currently taking weight loss medications or participated in a weight loss program within the past three months as assessed by the QI\n6. Current or history of eating disorders as assessed by the QI\n7. Unstable metabolic disease or chronic diseases as assessed by the QI\n8. Current or history of any significant diseases of the gastrointestinal tract as assessed by the QI\n9. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI\n10. Participants residing in the same household as another study participant unless they are enrolled consecutively (e.g. not actively enrolled at the same time)\n11. Type I or Type II diabetes\n12. Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis\n13. History of or current diagnosis with kidney and\u002For liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months\n14. Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI\n15. Self reported confirmation of glaucoma\n16. Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI\n17. Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable\n18. Individuals with an autoimmune disease or are immune compromised as assessed by the QI\n19. Self-reported confirmation of a HIV-, Hepatitis B- and\u002For C-positive diagnosis as assessed by the QI\n20. Self-reported confirmation of blood\u002Fbleeding disorders as assessed by the QI\n21. Chronic use of cannabinoid products (\\>2 times\u002Fweek) as assessed by the QI. Occasional users will be required to washout and abstain for the duration of the study period\n22. Regular use of tobacco or nicotine products in the past six months, as assessed by the QI. Occasional users will be required to washout and abstain for the duration of the study period\n23. Alcohol intake average of \\>2 standard drinks per day as assessed by the QI\n24. Alcohol or drug abuse within the last 12 months\n25. Current use of prescribed and\u002For over-the-counter (OTC) medications, supplements, and\u002For consumption of food\u002Fdrinks that may impact the efficacy and\u002For safety of the investigational product (Section 7.3)\n26. Blood donation 30 days prior to baseline, during the study, or a planned donation within 30 days of the last study visit\n27. Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI\n28. Individuals who are unable to give informed consent\n29. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant","ALL","18 Years","50 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to investigate the safety and efficacy of MB-1 on metabolic health in overweight and obese adults. The main question it aims to answer is:\n\nWhat is the difference in change in body weight from baseline at Day 84 between MB-1 and placebo?\n\nParticipants will be provided MB-1 or placebo and be assessed for anthropometric measurements, blood pressure, heart rate, and asked to complete appetite and satiety questionnaires and undergo a DEXA scan.",[27,28,29,30,31],"Obese","Overweight Adults","Obese Adults","Body Weight Control","BMI",[33,34,35,36],"Arrae","MB-1","Obesity","Overweight","NOT_YET_RECRUITING","2026-06-26",{"date":40,"type":41},"2026-06-30","ACTUAL",{"date":43,"type":21},"2026-08",{"date":45,"type":21},"2027-01",{"name":33,"class":47},"INDUSTRY",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":66,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":48},"100531527","trans-nasal-endoscopy-for-bariatric-patients-100531527","NCT06200961","Trans-nasal Endoscopy for Bariatric Patients","Use of Sedation-Free Transnasal Endoscopy to Improve Access and Lower Costs of Endoscopic Evaluations in a Bariatric Medical and Surgical Program","TNE","Inclusion Criteria:\n\n1. Patient 18 years of age and less than 90 years of age with clinically referred for esophagoscopy, gastroscopy, or esophagogastroduodenoscopy (EGD)\n2. Cared for in metabolic and bariatric clinic\n\nExclusion Criteria:\n\n1. Patient \\\u003C18 years of age\n2. Medically contraindicated to perform EGD or TNE\n3. Inability to provide informed consent","90 Years",{"count":59,"type":21},100,[24],"This study plans to learn if the EvoEndo Endoscopy system can be used to evaluate, provide and follow up care for upper gastrointestinal tract diseases in the bariatric population. The smallest current scope available for such a technique is an adult transnasal endoscope with a larger diameter, a pulmonary bronchoscope or Ear Nose and Throat (ENT) laryngoscope. This study is evaluating a newly Food and Drug Administration (FDA) cleared ultra-slim, single-use, endoscope specifically designed for transnasal endoscopy to evaluate its use in adult upper tract gastrointestinal diseases. If such a technique is successful it could improve the safety, cost, and access of endoscopic care for patients in need of an endoscopic evaluation for a bariatric medical condition.",[35,63,27,64,65],"Obesity, Morbid","GI Disorders","Gastrointestinal Diseases",[67,68,69,70],"Transnasal Endoscopy (TNE)","Esophagogastroduodenoscopy (EGD)","Upper Endoscopy","Endoscopy","RECRUITING","2026-06-23",{"date":74,"type":41},"2026-06-25",{"date":76,"type":41},"2026-04-20",{"date":78,"type":21},"2028-06",{"name":80,"class":81},"Christopher C. Thompson, MD, MSc","OTHER",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":88,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":93,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":101,"leadSponsor":103,"locationsCount":48},"100637753","effect-of-combined-resisted-training-and-protein-based-diet-on-frailty-in-sarcopenic-elderly-women-100637753","NCT07627919","Effect of Combined Resisted Training and Protein-based Diet on Frailty in Sarcopenic Elderly Women","Inclusion Criteria:\n\n* 1\\) Female gender 2) Age 60-70 years 3) BMI ≥ 30 kg\u002Fm2 4) Sarcopenic patients diagnosed by their physicians according to EWGSOP2 criteria (low muscle strength confirmed by handgrip strength or chair stand test, plus low muscle quantity confirmed by BIA or DXA), and SARC-F score \\>3.\n\n  5\\) Ambulatory and able to participate in exercise. 6) Stable medical condition. 7) The patients didn't follow any type of diet before the treatment at least 4 weeks ago.\n\n  8\\) Patients didn't follow any exercise program before treatment at least 4 weeks ago.\n\nExclusion Criteria:\n\n* 1\\) Sever cardiovascular, pulmonary, renal, or hepatic disease. 2) Uncontrolled diabetes or hypertension. 3) Neurological or musculoskeletal disorders prohibiting exercise 4) Cancer or other terminal illness. 5) Current use of anti-inflammatory drugs or steroids. 6) Metal implants prohibiting BIA assessment. 7) Cognitive impairment impairing ability to consent or follow instructions. 8) Using drugs that would affect metabolism or balance. 9) Using assistive devices for walking.","FEMALE","60 Years","70 Years",{"count":92,"type":21},60,[24],"Sixty obese elderly women will be recruited from Fawkia hospital outpatient clinic diagnosed by sarcopenia and randomly allocated into two groups for a 12-week intervention. Patients will be divided into 2 groups (A and B):\n\n* Group A (combined intervention group: n=30): will perform supervised resistance exercise training three times per week and follow a high-protein diet (1.3 g protein\u002Fkg\u002Fday)\n* Group B (control group: n=30): will receive a high-protein diet and general health advices and be asked to maintain their usual lifestyle. They will be offered the intervention post-study.",[27,96],"Sarcopenic Obesity","2026-05-30",{"date":99,"type":41},"2026-06-04",{"date":40,"type":21},{"date":102,"type":21},"2027-12-30",{"name":104,"class":81},"Cairo University",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":112,"sex":16,"minAge":17,"maxAge":113,"enrollmentInfo":114,"targetDuration":4,"studyType":22,"phases":116,"briefSummary":118,"conditions":119,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":48},"100635942","phase-1-a-pharmacokinetic-study-of-hdm1005-injection-in-participants-with-impaired-renal-function-and-healthy-participants-100635942","NCT07559240","A Pharmacokinetic Study of HDM1005 Injection in Participants With Impaired Renal Function and Healthy Participants","A Multicenter, Single-Dose, Parallel-Group, Open-Label Pharmacokinetic Study of HDM1005 Injection in Participants With Impaired Renal Function and Healthy Participants","Inclusion Criteria:\n\n* Aged between 18 and 75 years (inclusive), regardless of gender.\n* Body weight ≥50.0 kg for males and ≥45.0 kg for females; body mass index (BMI) between 19.0 and 35.0 kg\u002Fm² (inclusive).\n* For participants with renal impairment: prior diagnosis of chronic kidney disease (CKD). Absolute GFR calculated by CKD-EPI and BSA formula: ≥30 and \\\u003C60 mL\u002Fmin for moderate impairment; ≥15 and \\\u003C30 mL\u002Fmin for severe impairment.\n* For participants with normal renal function: aged 18 to 75 years (inclusive); body weight ≥50.0 kg (male) or ≥45.0 kg (female); BMI 19.0-35.0 kg\u002Fm².\n* In the investigator's opinion, suitable for the study based on medical history, clinical laboratory tests, vital signs, 12-lead ECG, and physical examination at screening.\n* Provide signed informed consent before any trial procedures; fully understand the trial content, procedures, and possible adverse reactions.\n* Able to communicate well with the investigator and understand and comply with all study requirements.\n\nExclusion Criteria:\n\n* Personal or family history of medullary thyroid carcinoma (MTC), thyroid C-cell hyperplasia, or multiple endocrine neoplasia type 2 (MEN2).\n* History of chronic pancreatitis, or an episode of acute pancreatitis or acute cholecystitis within 3 months prior to screening.\n* Severe hypoglycemic events or recurrent hypoglycemic events (≥3 episodes per week) within 3 months prior to screening.\n* For the renal impairment group: presence of obstructive urinary tract disease, acute kidney injury, or other clinically significant systemic diseases beyond chronic kidney disease and its complications, which in the investigator's opinion make the participant unsuitable. For the normal renal function group: presence of clinically significant diseases involving any of the following systems at screening (including but not limited to respiratory, circulatory, digestive, hematopoietic, endocrine, immune, skin, nervous, psychiatric, ear-nose-throat, etc.), which in the investigator's opinion make the participant unsuitable.\n* Known intolerance or allergy to GLP-1R and\u002For GIPR agonists, or known allergy to HDM1005 or any component of the formulation.\n* Major surgery within 6 months prior to screening, or incomplete healing of surgical incisions, or planned surgery during the study.\n* Blood donation or blood loss ≥400 mL, or use of blood products within 3 months prior to screening or between screening and dosing.\n* History of drug abuse (e.g., morphine, ketamine, tetrahydrocannabinolic acid, methamphetamine, methylenedioxymethamphetamine, cocaine) or positive urine drug test at screening.\n* History of needle phobia or hemophobia, difficulty with blood collection, or inability to tolerate venipuncture.\n* Any other condition (medical, psychological, psychiatric, social, or geographic factors) that, in the investigator's opinion, makes the participant unsuitable for the study.",true,"75 Years",{"count":115,"type":21},30,[117],"PHASE1","The purpose of this study is to evaluate the pharmacokinetic profile and safety of a single subcutaneous injection of HDM1005 solution in participants with impaired kidney function compared to healthy participants.",[36,27],"2026-05-05",{"date":122,"type":41},"2026-05-08",{"date":124,"type":21},"2026-05-15",{"date":126,"type":21},"2026-07-31",{"name":128,"class":47},"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":112,"sex":16,"minAge":17,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":22,"phases":139,"briefSummary":140,"conditions":141,"keywords":142,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":48},"100609823","phase-1-a-single-and-multiple-ascending-dose-study-of-hm17321-in-healthy-and-obese-participants-100609823","NCT07219589","A Single and Multiple Ascending Dose Study of HM17321 in Healthy and Obese Participants","A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM17321 in Healthy and Obese Participants","Inclusion Criteria:\n\n* Adults aged 18-65 years.\n* Part A: Healthy participants with BMI ≥20 kg\u002Fm² and ≤27 kg\u002Fm² at screening.\n* Part B: Healthy obese participants with BMI ≥30 kg\u002Fm² and ≤45 kg\u002Fm² at screening.\n* Stable body weight (\\\u003C5% change) in the past 3 months.\n* Able and willing to provide written informed consent.\n* Male participants must use contraception or remain abstinent from women of childbearing potential.\n* Female participants must not be pregnant or breastfeeding and use highly effective contraception if of childbearing potential.\n\nExclusion Criteria:\n\n* History of any bariatric procedure.\n* Uncontrolled thyroid disease (TSH \\>6.0 or \\\u003C0.4 mIU\u002FL).\n* Abnormal liver function or clinically significant liver disease\n\n  * Part A: ALT or AST ≥ ULN, or total bilirubin ≥ ULN\n  * Part B: ALT or AST \\>2× ULN, or total bilirubin \\>1.5× ULN\n* Abnormal pancreatic function\n\n  * Part A: amylase or lipase ≥ ULN\n  * Part B: amylase or lipase \\>3× ULN\n* Clinically significant cardiovascular disorders (e.g., myocardial infarction, congestive heart failure, long QT syndrome).\n* Abnormal renal function (eGFR \\\u003C60 mL\u002Fmin\u002F1.73 m²).\n* Positive test for hepatitis B, hepatitis C, or HIV at screening.\n* Women who are pregnant, planning to become pregnant, or breastfeeding.\n* History of drug or alcohol abuse within defined timeframes (e.g., alcohol \\>14 standard units\u002Fweek in past year, or positive drug screen).\n* Use of any investigational product within 30 days or 5 half-lives (whichever is longer) prior to screening.\n* Additional Exclusion Criteria for Part B\n\n  * HbA1c ≥6.5% or a history of diabetes mellitus (type 1 or type 2).\n  * Obesity induced by other endocrine disorders (e.g., Cushing syndrome).\n  * Use of weight control treatments (e.g., GLP-1 receptor agonists or other anti-obesity medications) and antihypertensive medications within 3 months prior to screening.\n  * Use of any lipid-lowering medications, unless on a stable dose for at least 3 months prior to screening.","65 Years",{"count":138,"type":21},90,[117],"This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HM17321 after single and multiple ascending doses in healthy and obese participants.",[35,27],[27,35],"2026-04-28",{"date":145,"type":41},"2026-05-04",{"date":147,"type":41},"2025-11-06",{"date":149,"type":21},"2027-03",{"name":151,"class":47},"Hanmi Pharmaceutical Company Limited",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":88,"minAge":17,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":22,"phases":161,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":48},"100624586","phase-1-a-study-looking-at-how-weekly-injections-of-two-hormones---gip-and-amylin---affect-stomach-related-side-effects-in-people-who-are-overweight-or-obese-100624586","NCT07411560","A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese","Single-centre Study Investigating the Role of Long-acting Subcutaneous Glucose-dependent Insulinotropic Polypeptide Receptor Agonist (GIP RA) in Combination With Long-acting Subcutaneous Amylin Receptor Agonist on Gastrointestinal Tolerability in Participants With Overweight or Obesity","Inclusion Criteria:\n\n* Female at birth.\n* Age 18-64 years (both inclusive) at the time of signing the informed consent.\n* Body mass index (BMI) between 27.0 kilograms per square meter (kg\u002Fm\\^2) and 39.9 kg\u002Fm\\^2 (both inclusive) at screening.\n* Overweight should be due to excess adipose tissue, as judged by the investigator.\n* Considered eligible with suitable veins for cannulation or repeated venepuncture, as judged by the investigator.\n* No clinically significant findings during medical history, physical examination, vital signs, electrocardiogram or clinical laboratory tests at the screening visit, as assessed by the investigator.\n\nExclusion Criteria:\n\n* Known or suspected hypersensitivity to study intervention(s) or related products.\n* Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using highly effective contraceptive method.\n* Current participation (i.e., dosing) in any other interventional clinical study within 90 days before screening.\n* Any condition which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.\n* Treatment with any medication prescribed for the indication of obesity or weight management within 90 days before screening, including incretin-based treatment(s).\n* Previous or planned (during the study period) obesity treatment with surgery. However, the following are allowed:\n\n  1. Liposuction and\u002For abdominoplasty, if performed greater than symbol (\\>) 1 year before screening.\n  2. Adjustable gastric banding, if the band has been removed \\> 1 year before screening.\n  3. Intragastric balloon, if the balloon has been removed \\> 1 year before screening.\n  4. Duodenal-jejunal bypass liner (e.g., Endobarrier), if the sleeve has been removed \\> 1 year before screening.","64 Years",{"count":59,"type":21},[117],"This trial is being done to look at the safety and effect of combining cagrilintide and NNC0480-0389 in people living with overweight and obesity compared to taking cagrilintide alone. In one period participants will get two medicines: cagrilintide and NNC0480-0389. In the other period, participants will get cagrilintide together with a placebo version of NNC0480-0389.The placebo looks like the real treatment but does not have any active medicine in it. Cagrilintide and NNC0480-0389 is a new medicine being tested to help people with type 2 diabetes and\u002For overweight or obesity. The trial medicines is not yet approved for use outside of clinical trials. Participants will receive the trial medicines the way the trial doctor has described. The study will last for about 4.5 months.",[36,27],"2026-04-07",{"date":166,"type":41},"2026-04-13",{"date":168,"type":41},"2026-02-09",{"date":170,"type":21},"2027-01-26",{"name":172,"class":47},"Novo Nordisk A\u002FS",{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":112,"sex":16,"minAge":17,"maxAge":180,"enrollmentInfo":181,"targetDuration":4,"studyType":22,"phases":183,"briefSummary":184,"conditions":185,"keywords":186,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":48},"100629837","phase-1-a-study-of-sa030-injection-in-overweight-or-obese-participants-100629837","NCT07479862","A Study of SA030 Injection in Overweight or Obese Participants","A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SA030 Injection in Overweight or Obese Participants","Inclusion Criteria:\n\n* You must be able to understand the study and sign a written consent form.\n* Men or women aged 18 to 55 years can join\n* Overweight or obese with a body mass index (BMI) between 25-40 kg\u002Fm\\^2(inclusive);\n* You should be generally healthy, The study doctor will check your medical history, vital signs, physical exam, blood and urine tests, Electrocardiogram, and abdominal. ultrasound. Minor issues are okay if the doctor thinks they are not medically important.\n* For female participants of childbearing potential: must be non-pregnant and non- lactating, and agree to use highly effective contraception throughout the study period;\n* For male participants of reproductive potential: must agree to use highly effective contraception during the study period to ensure effective contraception for sexual partners.\n\nExclusion Criteria:\n\n* You cannot join if you have lost or gained more than 5 percent of your body weight in the last 3 months.\n* You cannot participate if you previously had, or plan to have, weight-loss surgery or a weight-loss device during the study, except for the following procedures done more than 1 year before screening\n* Use of any over-the-counter medications, herbal supplements, or health products that may significantly affect weight or metabolism within 1 month prior to screening (e.g., orlistat, garcinia cambogia, ephedrine, etc.)\n* At screening, sitting systolic blood pressure more than of equals to 160 milli meters of mercury and\u002For diastolic blood pressure more than of equals to 100 mmHg, and deemed unsuitable for participation in this study by the investigator;\n* Severe psychiatric disorders or uncontrolled psychiatric conditions, including but not limited to schizophrenia, bipolar disorder, or depression, deemed unsuitable for participation in this study by the investigator;\n* If the screening ECG shows a prolonged QT\u002FQTc interval, and a repeat test confirms QTcF greater than 450 ms in males or greater than 470 ms in females, the participant will be excluded\n* Suffering from severe diseases, including but not limited to disorders of the nervous system, cardiovascular system, hematopoietic and lymphatic system, immune system, digestive system, urinary system, respiratory system, endocrine system, and history of malignancies, which the investigator judges may compromise safety or influence study results;\n* Co-infection with hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), or syphilis; or prior diagnosis of hepatitis A, D, or E without resolution;\n* Individuals who received a vaccine or live attenuated vaccine within 1 month prior to dosing, or who plan to receive a vaccine during the trial period; Major surgery within 6 months prior to screening, or planned surgery during the study period;\n* Severe infection or trauma within 4 weeks prior to screening;\n* Non-physiological blood loss more than or equals 200 milliliter within 1 month prior to study drug administration (including trauma, blood collection, or blood donation), or individuals planning to donate blood during the study period or within 60 days after dosing;\n* History of severe intolerance to subcutaneous injections (mild reactions such as local swelling or redness are permissible);\n* Individuals who have taken any prescription medication, herbal supplements, or over-the-counter drugs within 14 days prior to study drug administration;\n* Participation in other drug clinical trials within 3 months of this study's treatment initiation, or within 5 half-lives of other investigational drug exposure, or participation in siRNA or antisense oligonucleotide drug clinical trials within 6 months prior to this study's treatment initiation (participants who withdrew from the study before receiving the investigational drug may be eligible for this study);\n* Individuals who smoked more than 5 cigarettes or an equivalent amount of tobacco daily within 3 months prior to screening, or who are unable to abstain from smoking during the trial hospitalization period;\n* Weekly alcohol consumption exceeding 14 units within 3 months prior to screening (1 unit of alcohol ≈360 milli Liter beer or 45 milli Liter 40 percent alcohol spirits or 150 milli Liter wine), or those with a positive breath alcohol test on the day before dosing (breath alcohol content more than 0.0 milligram per100 mL), or those unable to abstain from alcohol during the trial hospitalization period;\n* Current or former drug users\u002Fsubstance abusers, or those with a positive urine drug screen on the day before dosing;\n* Other factors deemed unsuitable for trial participation by the investigator, such as potential for poor compliance.","55 Years",{"count":182,"type":21},40,[117],"This study is the first time SA030 is being given to people. The goal is to understand how safe it is, how well it is tolerated, and how the body processes and responds to a single dose of SA030 in individuals who are overweight or obese.\n\nOver the last few decades, more and more people around the world have become overweight or obese, and the numbers keep rising in almost every country. From 1990 to 2021, this problem grew steadily and reached its highest point in 2021.",[27,36],[187],"ALK7","2026-03-15",{"date":190,"type":41},"2026-03-18",{"date":192,"type":21},"2026-04-16",{"date":194,"type":21},"2027-03-03",{"name":196,"class":47},"Suzhou Siran Biotechnology Co.,Ltd.",{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":112,"sex":16,"minAge":203,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":22,"phases":206,"briefSummary":208,"conditions":209,"keywords":212,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":48},"100498462","phase-2-taxi-roadmap-realizing-optimization-around-diet-and-physical-activity-100498462","NCT05770570","Taxi ROADmAP (Realizing Optimization Around Diet And Physical Activity)","Inclusion Criteria:\n\nFor COMIDA participants only:\n\n* Self-Identifies as Mexican American or Mexican\n* Seeking services at the VDS of the Mexican Consulate\n* Prefers to speak in Spanish\n* All adults at least 18 years of age\n* Screens as obese (an adult who has a Body Mass Index (BMI) 30 or higher) or overweight (an adult who has a BMI between 25 - 29.9)\n* Agrees to be audio recorded\n\nFor SANOS focus group participants only:\n\n* Self-identifies as Hispanic\u002FLatino;\n* Seeking services at VDS or VDS Mobile;\n* Prefers to speak in Spanish;\n* At least 18 years of age;\n* Screens as obese (BMI ≥ 30 kg\u002Fm\\^2) or overweight (BMI of 25 - 29.9 kg\u002Fm\\^2);\n* Agrees to be audio recorded\n\nFor SANOS RCT participants only:\n\n* Self-identifies as Hispanic\u002FLatino;\n* Seeking services at VDS or VDS Mobile;\n* Prefers to speak in Spanish;\n* At least 18 years of age;\n* Screens as obese (BMI ≥ 30 kg\u002Fm\\^2) or overweight (BMI of 25 - 29.9 kg\u002Fm\\^2);\n* Owns a cell phone capable of receiving text messages;\n* Agrees to be audio recorded\n\nFor Family COMIDA participants only:\n\n* Self-Identifies as Hispanic\u002FLatino\n* Seeking services at the VDS (or has used VDS services in the past) of the Mexican - Consulate or VDS Mobile\n* Prefers to speak in Spanish\n* At least 18 years of age\n* Has at least one child under age 18 living in the same household\n* Owns a cell phone capable of receiving text messages\n* Willing to receive text messages (3 texts per week for 3 months)\n* Owns an internet connected device (eg, cell phone, tablet, etc) capable of conducting teleconference calls (eg, Zoom)\n\nFor ROADmAP RCT participants only:\n\n* At least 21 years of age\n* Full-time (drives at least 35 hours per week) licensed taxi\u002FFHV driver\n* Driver for at least 6 months\n* Seeking Health Fairs (or has used Health Fairs services in the past)\n* Speaks English, French, Bengali, or Spanish\n* Screens a as obese (BMI ≥ 30 kg\u002Fm2 \\[≥25 kg\u002Fm2 for South Asians\\]) or overweight (BMI of 25 - 29.9 kg\u002Fm2 s \\[23- 24.9 kg\u002Fm2 for South Asians\\])\n\n  * (BMI cut-offs are lower for South Asians, per WHO and American Diabetes Association recommendations)\n* Owns a cell phone capable of receiving text messages\n* Agrees to be audio-recorded\n\nFor ROADmAP Phase 2 participants only:\n\n* At least 21 years of age\n* Driver who participated in ROADmAP RCT or manager at a taxi garage, Uber, Lyft or driver serving\u002Funion\u002Forganization\n* Agrees to be audio-recorded\n\nExclusion Criteria:\n\nFor COMIDA participants only:\n\n* Will not be in the NYC area for the study duration (3-4 months) Is pregnant or might be pregnant\n* Lactating women\n* Presence of a chronic disease such as cancer, kidney disease, liver disease, etc. (Individuals with diabetes, lactose intolerance, and high blood pressure MAY still participate in the study)\n* Has dietary restrictions (i.e. liquid diet)\n* Does not have a phone that accepts text messages or unwilling to accept text messages\n* Presence of a serious psychiatric or cognitive impairment likely to preclude meaningful informed consent and adherence to the protocol per the consenting professional\"s judgment\n* Has another family member already enrolled in COMIDA (as determined by patient report)\n\nFor SANOS focus group participants only:\n\n* Is pregnant or might be pregnant; lactating women;\n* Self-reported presence of a chronic disease such as cancer, kidney disease, liver disease, etc. (individuals with HTN and DM may still participate);\n* Has dietary restrictions (i.e. liquid diet);\n* Has a household member who has already participated (or agreed to participate);\n\nFor SANOS RCT participants only:\n\n* Is pregnant or might be pregnant; lactating women; for the study duration (6 months)\n* Self-reported presence of a chronic disease such as cancer, kidney disease, liver disease, etc. (individuals with HTN and DM may still participate); restricting diet;\n* Currently has dietary restrictions (i.e. liquid diet);\n* Has a household member who has already participated (or agreed to participate);\n* Has already participated in the study\n* Will not be in the NY Metropolitan area for the study duration (6 months) Works for or with the Mexican consulate (including employment and\u002For collaborative or volunteer services)\n\nFor Family COMIDA participants only:\n\n* Is pregnant or might be pregnant; lactating women for the study duration (3 months)\n* Will not be in the NY Metropolitan area for the study duration (3 months) Presence of a chronic disease such as cancer, kidney disease, liver disease, etc. (Individuals with diabetes, lactose intolerance, and high blood pressure MAY still participate in the study)\n* Has dietary restrictions (i.e. liquid diet)\n* Has another family member who has already participated in COMIDA or SANOS\n* Has already participated in the study\n* Works for or with the Mexican consulate (including employment and\u002For collaborative or volunteer services)\n\nFor ROADmAP RCT participants only:\n\n* Is pregnant or might be pregnant; lactating women; for the study duration (12 months)\n* Self-reported presence of a chronic disease such as cancer, kidney disease, liver disease, etc. (individuals with HTN and DM may still participate) that may restrict diet\n* Currently has dietary restrictions (i.e. liquid diet)\n* Has a household member who has already participated (or agreed to participate)\n* Has already participated in the study\n* Will not be in the NY Metropolitan area for 6 months from study enrollment\n* Is currently taking Ozempic, Wegovy, Mounjaro, Rybelsus, Trulicity Saxenda, Victoza, Phentermine (Adipex, Lomaira), Extended-release Phentermine\u002FTopiramate (Qsymia), Extended-release Naltrexone\u002FBupropion (Contrave), Plenity, Orlistat (Xenical) or Other GLP-1 receptor agonist, or any other drug to treat obesity or there is less than 7 weeks since last dosage.\n* Has undergone weight loss\u002Fbariatric surgery or is planning to undergo such surgery in the next 12 months.","21 Years",{"count":205,"type":21},1785,[207],"PHASE2","The researchers will conduct 'Taxi ROADmAP (Realizing Optimization Around Diet And Physical activity)', which also utilizes MOST, and the same 4 obesity intervention components as in SANOS, but targets the overweight\u002Fobesity crisis in another at-risk, low socioeconomic status (SES) population, taxi and for-hire vehicle (FHV) drivers (Lyft, Uber, etc.). ROADMAP also utilizes an effectiveness- implementation hybrid type 1 design. Hybrid trials, which blend effectiveness and implementation studies, can lead to more rapid translational uptake and more effective implementation. Taxi and FHV drivers are a growing, multilingual, hard-to-reach, predominantly immigrant and minority essential worker population. There are over 750,000 licensed taxi and FHV drivers in in the U.S. and over 185,000 in New York City (NYC). They have higher rates of overweight\u002Fobese range body mass index (BMI) than New Yorkers in general (77% vs 56%) and have high rates of elevated waist circumference, sedentary behavior, poor diets, and health care services underutilization. ROADmAP will test 4 evidence- and theory-based (Social Cognitive Theory \\[SCT\\]) behavior change intervention components. We will use MOST to identify which of the 4 components contribute most significantly and cost-effectively to weight loss among NYC drivers recruited at workplace health fairs (HFs) and virtually. Objectives are to apply MOST to design an optimized version of a scalable, lifestyle intervention for taxi\u002FFHV drivers, and then to conduct a mixed methods multistakeholder process evaluation to facilitate widespread intervention implementation.",[36,210,211,35,27],"Overweight and Obesity","Overweight or Obesity",[213,36,210,211,35,27,214],"Focus Groups","Memorial Sloan Kettering Cancer Center","2026-01-23",{"date":217,"type":41},"2026-01-26",{"date":219,"type":41},"2022-12-22",{"date":221,"type":21},"2027-08-11",{"name":214,"class":81},{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":227,"acronym":4,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":16,"minAge":229,"maxAge":230,"enrollmentInfo":231,"targetDuration":4,"studyType":232,"phases":4,"briefSummary":233,"conditions":234,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":48},"100505115","exercise-response-in-humans-with-obesity-100505115","NCT05857150","Exercise Response in Humans With Obesity","Inclusion Criteria:\n\n* Obese men and women ≥ 20 and ≤ 45 years of age.\n\nExclusion Criteria:\n\n* Diabetes or fasting plasma glucose \\>126 mg\u002FdL\n* Anemia (female subjects hemoglobin of \\\u003C11 g\u002Fdl and male subjects hemoglobin \\\u003C12 g\u002Fdl)\n* Active coronary artery disease or history of unstable macrovascular disease (unstable angina, myocardial infarction, stroke, and revascularization of coronary, peripheral or carotid artery within 3 months of recruitment)\n* Renal failure (serum creatinine \\> 1.5mg\u002Fdl)\n* Chronic active liver disease defined as aspartate aminotransferase (AST)\\>144 IU\u002FL or alanine transaminase (ALT) \\>165 IU\u002FL)\n* Oral warfarin group medications or history of blood clotting disorders.\n* Smoking\n* Pregnancy or breastfeeding\n* Alcohol consumption greater than 2 glasses\u002Fday or other substance abuse\n* Untreated or uncontrolled hypothyroidism\n* Debilitating chronic disease (at the discretion of the investigators)","20 Years","45 Years",{"count":20,"type":21},"OBSERVATIONAL","This study is being done to understand how chronic inflammation affects muscle function and responses to exercise.",[27],"2025-08-22",{"date":237,"type":41},"2025-08-29",{"date":239,"type":41},"2023-09-22",{"date":241,"type":21},"2029-07",{"name":243,"class":81},"Mayo Clinic",{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":248,"acronym":249,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":88,"minAge":251,"maxAge":252,"enrollmentInfo":253,"targetDuration":4,"studyType":22,"phases":255,"briefSummary":257,"conditions":258,"keywords":260,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":48},"100502253","phase-3-role-of-semaglutide-in-restoring-ovulation-in-youth-and-adults-with-polycystic-ovary-syndrome-100502253","NCT05819853","Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome","RESTORE","Inclusion Criteria\n\n1. Female\n2. Ages 12-35 years\n3. Sedentary- less than 2 hours of moderate (jogging, swimming etc.) exercise a week.\n4. Oligomenorrhea, on or off metformin, as defined per age category in the most recent 2018 PCOS international guidelines\n5. Initial BMI based on age and weight:\n\n   1. If \\\u003C18 years, initial BMI percentile ≥95\n   2. If 18-35 years, initial BMI ≥30 kg\u002Fm2 OR initial BMI ≥27 kg\u002Fm2 with at least one weight-related comorbid condition, e.g., hypertension or dyslipidemia\n   3. Must be weight stable within ±5kg in the 3 months prior to enrollment\n6. Diagnosed with PCOS per the most stringent NIH criteria with adaptation for adolescents (oligomenorrhea \\>24 months post-menarche or primary amenorrhea after age 15 years and clinical\u002F biochemical hypertestosteronemia\n7. Participants cannot be on hormonal contraception, so participants should remain abstinent or use reliable non-hormonal contraception (e.g., copper IUD) for the entire study period. For participants who receive semaglutide, they should avoid pregnancy for at least 2 months after stopping medication to avoid fetal exposure to the medication.\n8. For participants in the metformin + semaglutide group, participants must have been stable on ≥ 1500 mg of metformin a day for at least 3 months by time of screening\n\nExclusion Criteria:\n\n1. Diagnosed with or have a family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Family history of medullary thyroid cancer or thyroid nodule palpated by endocrinologist at screening. - Per approved drug label\n2. Use of medications known to affect insulin sensitivity: metformin (cannot have been used in the 3 months prior to screening for the untreated arm of the study), chronic oral steroids, oral glucocorticoids within 10 days, atypical antipsychotics, immunosuppressant agents, HIV medications, estrogen-containing hormonal contraception (cannot have been used in the 6 months prior to screening), progesterone-containing hormonal contraception (cannot have been used in the 3 months prior to screening). Dermal patch or vaginal ring contraception methods. Weight loss medications or stimulants. Use of other products containing other GLP-1 agonists.\n3. Weight loss medications in the last 6 months\n4. Currently pregnant or breastfeeding women. Development of pregnancy during the study period will necessitate withdrawal from the study.\n5. Severe illness requiring hospitalization within 60 days.\n6. Diabetes, defined as Hemoglobin A1C ≥6.5%\n7. Anemia, defined as Hemoglobin \\\u003C 12 mg\u002FdL\n8. Diagnosed major psychiatric or developmental disorder limiting informed consent.\n\n10\\) Known liver disease other than NAFLD, or AST or ALT \\>125 IU\u002FL. 11) Personal history of pancreatitis 12) Known renal disease of any severity or an eGFR at screening of \\\u003C45ml\u002Fmin\u002F1.73m2 13) History of severe GI disease (e.g., gastroparesis) 14) History of gallstones 15) Untreated thyroid disease 16) History of hypersensitivity to semaglutide 17) Other causes of hyperandrogenism (example: tumor, CAH) or amenorrhea (untreated thyroid disease, tumor, primary ovarian failure, prolactinoma).\n\n18\\) Active symptoms or undergoing treatment for anorexia nervosa or binging\u002Fpurging disorder 19) Desiring pregnancy in the next 12-18 months. 20) Bariatric surgery 21) Use of THC (smoking or edible) more than 3 days a week 22) Alcohol use-drinking more than 2 drinks, more than 3 days a week 23) Any potential participants who cannot\u002Fwill not commit to abstinence, use of a copper intrauterine device (IUD), or use of double barrier forms of contraception.","12 Years","35 Years",{"count":254,"type":21},80,[256],"PHASE3","Girls and women 12-35 years old with obesity and polycystic ovarian syndrome who are on or off metformin, will receive a glucagon like peptide-1 receptor agonist intervention for 10 months to induce metabolic changes, weight loss and improve reproductive abnormalities.",[259,27],"PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries",[261,262],"PCOS","semaglutide","2025-08-21",{"date":265,"type":41},"2025-08-28",{"date":267,"type":41},"2023-11-03",{"date":269,"type":21},"2028-06-30",{"name":271,"class":81},"University of Colorado, Denver",{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":277,"acronym":278,"eligibilityCriteria":279,"healthyVolunteers":11,"sex":16,"minAge":280,"maxAge":17,"enrollmentInfo":281,"targetDuration":4,"studyType":22,"phases":282,"briefSummary":283,"conditions":284,"keywords":285,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":48},"100189057","dynamo-a-tailored-lifestyle-promotion-intervention-among-pediatric-patients-with-cardiometabolic-risk-factors-100189057","NCT01736748","Dynamo: a Tailored Lifestyle Promotion Intervention Among Pediatric Patients With Cardiometabolic Risk Factors","Implementing Dynamo: a Tailored Lifestyle Promotion Intervention Among Pediatric Patients With Cardiometabolic Risk Factors","CIRCUIT","Inclusion Criteria:\n\n* children ages 6 to 18 years of age with a BMI \\> 95th percentile for age and sex\n\nExclusion Criteria:\n\n* children with a physical or psychological condition that would impair their ability to participate in physical activity","6 Years",{"count":59,"type":21},[24],"The Dyn@mo lifestyle intervention (CHU Sainte-Justine, Quebec, Canada) targets children and adolescents aged 6 to 17 years old with cardiometabolic risk factors, such as obesity, hypertension, disorders in glucose regulation or dyslipidemia. Its primary goal is to promote physical activity and reduce sedentary time to improve childrens' cardiometabolic profile. To do so, the intervention relies on gathering data on mobility and physical activity using wearable sensors. These data provide a detailed picture of real-life conditions and physical activity levels, improving the health care professional's ability to tailor counseling. The investigators are presently in the implementation phase of this intervention.",[27],[286,287,288,289,290,291],"obesity","physical activity","metabolism","environment","obese children, as defined by a body mass index > 95th percentile","for age and sex","2025-05-20",{"date":294,"type":41},"2025-05-25",{"date":296,"type":41},"2012-08",{"date":298,"type":21},"2030-12",{"name":300,"class":81},"St. Justine's Hospital",{"id":302,"slug":303,"hasResults":11,"nctId":304,"briefTitle":305,"officialTitle":306,"acronym":307,"eligibilityCriteria":308,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":89,"enrollmentInfo":309,"targetDuration":4,"studyType":232,"phases":4,"briefSummary":310,"conditions":311,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":48},"100382102","adipose-inflammation-and-diabetes-fab-100382102","NCT04255264","Adipose Inflammation and Diabetes (FAB)","Adipose Tissue Inflammation and Diabetes Development (Fettvävsinflammation Och Diabetesutveckling)","FAB","Inclusion Criteria:\n\n* BMI 30-40 kg\u002Fm2\n* Ptos (i.e. excess skin) \\> 3 cm\n* Patient underwent gastric bypass surgery \\>2 years ago\n* Patient has had a stable weight ≥6 months at the time of operation\n* Patient does not smoke (min 6 weeks prior to surgery)\n\nExclusion Criteria:\n\n* Patients who do not understand spoken and written Swedish\n* American Society of Anesthesiologists (ASA) classification ≥ 3\n* Neurological, orthopedic or rheumatologic injury or illness affecting physical ability\n* Preoperatively known hernia requiring surgical operation\n* Severe mental illness",{"count":5,"type":21},"The study investigates whether the addition of resolution molecules can inhibit inflammation and insulin resistance in human tissue taken from obese individuals, and whether the results of these studies correlate with patient-specific resolution phenotypes.",[27],"2025-05-05",{"date":314,"type":41},"2025-05-06",{"date":316,"type":41},"2019-08-01",{"date":318,"type":21},"2027-06-30",{"name":320,"class":81},"Göteborg University",{"id":322,"slug":323,"hasResults":11,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":327,"eligibilityCriteria":328,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":329,"enrollmentInfo":330,"targetDuration":4,"studyType":22,"phases":331,"briefSummary":332,"conditions":333,"keywords":334,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":341,"completionDateStruct":343,"leadSponsor":345,"locationsCount":4},"100588611","empowering-healthy-lifestyle-behavior-to-prevent-and-control-obesity-in-young-adults-100588611","NCT06943651","Empowering Healthy Lifestyle Behavior to Prevent and Control Obesity in Young Adults","Empowering Healthy Lifestyle Behaviour Through Personalized Intervention Portfolios to Prevent and Control Obesity in Young Adults - A Pilot Study","HW8YAPilot","Inclusion criteria:\n\n* To be young adult (age 18-25 y)\n* To reside in Portugal\n* To be overweight (BMI between 25-30 kg\u002Fm2)\n* Women and men\n\nExclusion Criteria:\n\n* To have a manifest chronic diseases (e.g. cancer)\n* To be already in energy restriction or following a specific diet (on their own or advised by their physician)\n* To have eating behavior pathologies.","25 Years",{"count":182,"type":21},[24],"This human study will be a pilot trial that will precede a planned more long-term intervention trial. It will focus on young adults (age 18 to 25 y). The main purpose is to study whether the healthy lifestyle recommender solution, reflecting a multi-portfolio intervention and developed within this project, is well accepted by the participants, has a decent adherence (i.e. user time of the app), and whether the overall design is well suited to the participants, in order that they will improve dietary habits. This study will be of longitudinal design without a control group.\n\nAt present, numbers of persons with overweight and obesity continue to grow in most countries worldwide. Young adults are at risk since in in this period of life most people start to be independent from their families, with the consequent decisions about their food and lifestyle choices. It is frequent that at this time an increase in irregularity of meals and unhealthy food choices, occurs, together with changes in physical activity habits and social or individual pressures. Because of this, it is essential to give tools to these individuals that will allow them to make healthy choices and to have healthy habits, since they will be the future adult population that will raise and inspire the next generation. As solutions to combat the trend toward increasing overweight and obesity are much in need, the present study aims to intervene with the developed healthy lifestyle recommender solution to address various factors known to constitute a risk for developing obesity, including socio-demographic aspects, psychological\u002Fbehavioural ones, physical activity, dietary patterns, among other. Such a multi-dimensional portfolio approach is believed to be very much needed for the prevention of obesity and co-morbidities, and the personalization of the solution, as well as the nudging\u002Fgamification.",[27,36],[35,36,335,336,337],"Digital twin","Obesity prevention","Lifestyle","2025-04-17",{"date":340,"type":41},"2025-04-24",{"date":342,"type":21},"2025-04-21",{"date":344,"type":21},"2025-07-31",{"name":346,"class":81},"University of Évora",{"id":348,"slug":349,"hasResults":11,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":4,"eligibilityCriteria":353,"healthyVolunteers":112,"sex":88,"minAge":230,"maxAge":180,"enrollmentInfo":354,"targetDuration":4,"studyType":22,"phases":355,"briefSummary":356,"conditions":357,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":48},"100575984","pilates-mat-exercises-training-on-functional-performance-in-middle-age-obese-women-100575984","NCT06779383","Pilates Mat Exercises Training on Functional Performance in Middle Age Obese Women","Effect of Pilates Mat Exercises Training on Functional Performance in Middle Age Obese Women: Randomized Controlled Trial","Inclusion Criteria:\n\n* women\n\n  * BMI between 30 to 34.9 kg\u002Fm2\n  * Age will range from 45-55 years old.\n\n    1. Exclusion criteria\n\nExclusion Criteria:\n\n* Cardiac diseases\n\n  * Liver diseases\n  * Hypertension\n  * Musculoskeletal disease",{"count":92,"type":21},[24],"• Aim of the study: This study will aim to investigate the effects of a 12-week Pilates-mat exercise program on the functional performance in middle age obese women.\n\nMaterials and Methods:\n\nsixty obese women patients (ages 45-55 years old) with a body mass index (BMI) 30 -34.9 kg\u002Fm2.Women will be randomly assigned into experimental group(Pilates) or control group, (3 times\u002Fweek, 60 min\u002Fsession) their age from 45 to 55 yrs. The Pilates exercises were performed on mats. The functional performance on one-leg stance (OLS), five-times-sit-to-stand (STS) and 6-min walk (6 MW) tests was evaluated before and after the 12-week Pilates training or control follow-up period.",[27],"2025-01-12",{"date":360,"type":41},"2025-01-16",{"date":362,"type":21},"2025-01-20",{"date":364,"type":21},"2025-05-29",{"name":366,"class":81},"Badr University",{"id":368,"slug":369,"hasResults":11,"nctId":370,"briefTitle":371,"officialTitle":371,"acronym":4,"eligibilityCriteria":372,"healthyVolunteers":112,"sex":373,"minAge":17,"maxAge":374,"enrollmentInfo":375,"targetDuration":4,"studyType":22,"phases":376,"briefSummary":377,"conditions":378,"keywords":379,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":390,"locationsCount":48},"100559325","the-effect-of-mask-combined-with-high-flow-oxygen-on-preoxygenation-during-induction-of-general-anesthesia-in-obese-patients-100559325","NCT06562660","The Effect of Mask Combined With High Flow Oxygen on Preoxygenation During Induction of General Anesthesia in Obese Patients","Inclusion Criteria:\n\n1. Participants ranged in age from 18 to 80 with BMI≥30 kg\u002Fm2.\n2. Participants are male obese patients undergoing elective non-thoracic surgery\n\nExclusion Criteria :\n\n1. patients were kept awake during the intubation due to cervical spine pathology.\n2. Patients with unstable hemodynamics.\n3. Patients with airway inflammatory diseases, including asthma, chronic obstructive pulmonary disease (COPD), lung cancer, pulmonary fibrosis and cystic fibrosis.\n4. Patients with upper respiratory infection and nasal blockage.\n5. Patients with Hypersensitivity to the drug.","MALE","80 Years",{"count":92,"type":21},[24],"There is a risk of airway-related incidents during anaesthesia associated with obesity. High-flow nasal oxygen is advocated for perioperative preoxygenation in obese patients to reduce airway adverse reactions. However, there have been no reports on whether smoking behaviors have an impact on obese men's Apnoeic oxygenation with high-flow nasal.This study compared the effects of smoking on the duration of safe apnoea times in obese males.",[27],[380,381,382],"High-Flow Nasal Oxygen","Obese Men","Smoking","2024-09-18",{"date":385,"type":41},"2024-09-20",{"date":387,"type":41},"2024-05-01",{"date":389,"type":21},"2025-03-01",{"name":391,"class":81},"Henan Provincial People's Hospital",{"id":393,"slug":394,"hasResults":11,"nctId":395,"briefTitle":396,"officialTitle":396,"acronym":4,"eligibilityCriteria":397,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":398,"targetDuration":4,"studyType":232,"phases":4,"briefSummary":400,"conditions":401,"keywords":403,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":48},"100561470","validity-and-reliability-of-the-6-minute-pegboard-ring-test-in-obese-individuals-100561470","NCT06590584","Validity and Reliability of the 6-minute Pegboard Ring Test in Obese Individuals","Inclusion Criteria:\n\n* BMI value of 30 kg\u002Fm2 and above,\n* Ability to ambulate,\n* Being 18 years of age and above,\n* Being a volunteer.\n\nExclusion Criteria:\n\n* Use of anti-obesity medication,\n* Pregnancy,\n* Latent autoimmune diabetes,\n* Chronic renal failure,\n* Active or serious infections,\n* Liver failure,\n* Recent major cardiovascular events,\n* Unstable angina,\n* Heart failure (NYHA III-IV)\n* Respiratory failure, cardiac arrhythmias, neoplastic diseases, and neurological or musculoskeletal disorders that limit testing.",{"count":399,"type":21},50,"Obesity is a major public health problem that causes numerous diseases and problems that threaten human health. The prevalence of obesity has increased worldwide in the last \\~50 years and has reached pandemic levels. Similar results are seen in Turkey, and according to the results of the Turkey Health Survey, 20.2% of people aged 15 and over were obese and 35.6% were pre-obese in 2022. Obesity represents a major health problem as it significantly increases the risk of diseases such as type 2 diabetes mellitus, fatty liver disease, hypertension, myocardial infarction, stroke, dementia, osteoarthritis, obstructive sleep apnea and various cancers, thus contributing to a decrease in both quality of life and life expectancy. Obesity is also associated with unemployment, social disadvantages and reduced socio-economic productivity, thus representing an increasing economic burden.\n\nObesity is associated with physiological changes at the muscle level, including a decrease in capillary density and blood flow, thus limiting the supply of oxygen and energy resources. Along with the limited blood flow, muscle cells in obese individuals have a decrease in the relative number and size of mitochondria required for energy supply. This leads to a limitation in upper limb activities.\n\nThis activity restriction is related to many activities of daily living that involve unsupported upper extremity movements that lead to dyspnea and fatigue in patients with cardiopulmonary disease. Therefore, determining the strength, endurance and exercise capacity of the upper extremities emerges as an important issue in obesity management. One of the tests that serve this purpose is the 6-minute pegboard ring test (6PBRT), which has been found to be valid and reliable in patients with chronic obstructive pulmonary disease and asthma. However, when the literature is examined, it is seen that 6PBRT has not been studied in obese individuals. Therefore, the aim of the study is to investigate the validity and reliability of 6PBRT in obese individuals.\n\nThe main question it aims to answer is:\n\n\\- Is 6PBRT a valid and reliable method to assess upper extremity functional capacity in patients wit obesity?",[402,35,27],"Obese Patients",[286,404,405,406],"exercise test","upper extremity","arm exercise endurance","2024-09-09",{"date":409,"type":41},"2024-09-19",{"date":411,"type":41},"2024-08-01",{"date":413,"type":21},"2025-06-28",{"name":415,"class":81},"Selcuk University",{"id":417,"slug":418,"hasResults":11,"nctId":419,"briefTitle":420,"officialTitle":421,"acronym":4,"eligibilityCriteria":422,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":113,"enrollmentInfo":423,"targetDuration":4,"studyType":22,"phases":424,"briefSummary":425,"conditions":426,"keywords":429,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":433,"lastUpdatePostDateStruct":434,"startDateStruct":436,"completionDateStruct":438,"leadSponsor":440,"locationsCount":442},"100504158","phase-2-the-effects-of-the-golo-for-life-plan-with-release-supplement-on-glycemic-control-and-weight-in-overweight-and-obese-adults-with-prediabetes-or-type-2-diabetes-100504158","NCT05844644","The Effects of the GOLO for Life® Plan With Release Supplement on Glycemic Control and Weight in Overweight and Obese Adults With Prediabetes or Type 2 Diabetes","An Open Label Study Evaluating the Effects of the GOLO for Life® Plan With Release Supplement on Glycemic Control and Weight in Overweight and Obese Adults With Prediabetes or Type 2 Diabetes","Inclusion Criteria:\n\n1. Males and females between the age of 18-75 years, inclusive, at screening\n2. BMI ≥25 kg\u002Fm2\n3. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening\n\n   Or,\n\n   Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months prior to enrollment. Acceptable methods of birth control include:\n   * Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)\n   * Double-barrier method\n   * Intrauterine devices\n   * Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)\n   * Vasectomy of partner at least 6 months prior to screening\n   * Abstinence and agrees to use contraception if planning on becoming sexually active\n4. Prediabetes or Type 2 Diabetes with HbA1c ≥6.0% to \\\u003C9% with stability of disease and no change in diabetic medication in the past three months, if applicable.\n5. Self-reported stable body weight in the three months prior to baseline, as assessed by the QI\n6. Motivated and ability to comply with G4LP guidelines as assessed by a Self-Motivation Questionnaire at screening (see Appendix 16.3)\n7. Agrees to maintain current lifestyle habits as much as possible throughout the study depending on ability to maintain the following: medications, supplements (unless excluded), and sleep\n8. Willingness and ability to complete questionnaires, records, and diaries associated with the study, adhere to dietary and exercise guidelines, and to complete all clinic visits\n9. Provided voluntary, written, informed consent to participate in the study\n\nExclusion Criteria:\n\n1. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study\n2. Allergy, sensitivity, or intolerance to the investigational product ingredients\n3. Type 1 diabetes\n4. Type 2 diabetes if on insulin treatment\n5. Gastric bypass surgery or other surgeries to induce weight loss\n6. Current participation or participation within the last three months in any weight loss or diet programs\n7. Current or history of eating disorders, as assessed by the QI\n8. Obesity-induced by metabolic or endocrinologic disorders (ex. acromegaly, hypothalamic obesity), as assessed by the QI\n9. Current or history of significant diseases of the gastrointestinal tract, as assessed by the QI\n10. Chronic inflammatory diseases, as assessed by the QI\n11. History of gout and have had a flare up within 12 months, as assessed by the QI\n12. Current unstable diagnosis with kidney and\u002For liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months\n13. Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI\n14. Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI\n15. Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable\n16. Current use of any prescribed or over-the counter medications and\u002For supplements that may affect glycemic control, body weight, or metabolism, as assessed by the QI\n17. Regular use of tobacco products within 6 months of baseline and during the study period, as assessed by the QI\n18. Chronic inhalation and edible use of cannabinoid products (\\>1 time\u002Fmonth). Occasional users must agree to wash out and abstain during the study period\n19. Alcohol intake average of \\>2 standard drinks per day\n20. Alcohol or drug abuse within the last 12 months\n21. Clinically significant abnormal laboratory results at screening, as assessed by the QI\n22. Blood donation 30 days prior to baseline, during the study, or a planned donation within 30 days of the last study visit\n23. Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI\n24. Individuals who are unable to give informed consent\n25. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant",{"count":59,"type":21},[207],"The objective of this study is to investigate the efficacy and safety of the GOLO for Life® Plan (G4LP) and Release supplementation on glycemic control and weight in overweight and obese adults with Prediabetes or Type 2 Diabetes. The change in glycemic control from baseline at Days 90 and 180 following the G4LP and supplementation with Release will be assessed. Additionally, the safety and tolerability of the G4LP and Release supplementation will be measured by the occurrence of and\u002For changes in pre-emergent and post-emergent adverse events (AEs).",[427,27,36,428],"Type 2 Diabetes","Prediabetes",[427,430,431,432,428],"obese","overweight","glycemic control","2024-07-25",{"date":435,"type":41},"2024-07-26",{"date":437,"type":41},"2023-04-20",{"date":439,"type":21},"2025-01",{"name":441,"class":47},"Golo",2,{"id":444,"slug":445,"hasResults":11,"nctId":446,"briefTitle":447,"officialTitle":448,"acronym":4,"eligibilityCriteria":449,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":136,"enrollmentInfo":450,"targetDuration":4,"studyType":22,"phases":452,"briefSummary":454,"conditions":455,"keywords":458,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":462,"lastUpdatePostDateStruct":463,"startDateStruct":465,"completionDateStruct":467,"leadSponsor":469,"locationsCount":4},"100532710","phase-4-efficacy-of-henagliflozin-for-weight-loss-in-obesity-without-diabetes-100532710","NCT06216340","Efficacy of Henagliflozin for Weight Loss in Obesity Without Diabetes","Efficacy of Henagliflozin for Weight Loss in Obesity Without Diabetes: a Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial","Inclusion Criteria:\n\n1. 18 years old≤age≤65 years old, regardless of gender and race\n2. Nondiabetic population: without hypoglycemic treatment, FPG\\\u003C7.0 mmol\u002Fl, PPG\\\u003C11.1 mmol\u002Fl, and HbA1c\\\u003C6.5%\n3. obesity: BMI≥28 kg\u002Fm2\n4. Stable weight: weight change less than 5kg in the past 3 months\n5. Ability to understand and sign the informed consent form\n\nExclusion Criteria:\n\n1. Allergies to Henagliflozin or its formulations;\n2. Participants have been definitely diagnosed with diabetes;\n3. HbA1c≥6.5 % or FPG≥7.0 mmol\u002Fl, or PPG≥11.1 mmol\u002Fl;\n4. Participants have used glucagon-like peptide-1 (GLP-1) receptor agonists, sodium glucose linked transporter-2 (SGLT-2) inhibitors, or other weight loss related drugs within the past 3 months;\n5. History of bariatric surgery;\n6. Untreated or uncontrolled hypothyroidism\u002Fhyperthyroidism;\n7. High risk of urinary tract infection;\n8. Obesity induced by other endocrinologic disorders (e.g. Cushing's Syndrome);\n9. Diagnosis of congenital glucose-galactose malabsorption or familial renal glycosuria\n10. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 2.5 times the upper limit of the normal range (UNL); Total bilirubin (TBIL) ≥ 2.0 times the upper limit of the normal range;\n11. estimated glomerular filtration rate (eGFR)\\\u003C30 mL\u002Fmin\u002F1.73 m2 or end-stage kidney disease, or requiring dialysis;\n12. History of major depressive disorder or other severe psychiatric disorders, e.g. schizophrenia, bipolar disorder within the last 2 years;\n13. Uncontrolled treated\u002Funtreated hypertension (systolic blood pressure ≥160 mm Hg and\u002For diastolic blood pressure ≥100 mm Hg)\n14. myocardial infarction, unstable angina, revascularization surgery, or cerebrovascular diseases within the past 3 months;\n15. Cancer (past or present, except basal cell skin cancer or squamous cell skin cancer) or other severe diseases, which in the investigator's opinion could interfere with the results of the trial;\n16. Females of child-bearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (adequate contraceptive measures as required by local law or practice) within 24 months;\n17. Participation in a clinical trial within the last 3 months prior to screening;\n18. Previous history of gestational diabetes;\n19. Previous history of eating disorders;\n20. Current or history of treatment with medications that may cause significant weight gain, within 3 months prior to screening, including systemic corticosteroids (except for a short course of treatment, i.e. 7-10 days), tri-cyclic antidepressants, atypical antipsychotic and mood stabilizers (e.g. imipramine, amitriptyline, mirtazapine, paroxetine, phenelzine, chlorpromazine, thioridazine, clozapine, olanzapine, valproic acid and its derivatives, and lithium);\n21. Diet attempts using herbal supplements or over-the-counter medications within 3 months before screening\n22. Any lifetime history of a suicidal attempt or a history of any suicidal behavior in the last month prior to randomization;\n23. Surgery scheduled for the trial duration period, except for minor surgical procedures, at the discretion of the investigator\n24. Known or suspected abuse of alcohol or narcotics\n25. Subjects from the same house hold participating in the trial\n26. Other situations which were inappropriate to the trial, at the discretion of the investigator",{"count":451,"type":21},300,[453],"PHASE4","This trial is conducted in China. The purpose of the 24-week trial is to investigate the efficacy of henagliflozin to induce body weight loss and the purpose of the extension is to evaluate the hypoglycemic effect of henagliflozin in obese subjects without diabetes.\n\nTrial has the following two periods: 1) A 12-week randomized, double-blind, placebo-controlled, multi-center trial for evaluating the efficacy of henagliflozin to induce body weight loss; 2) A 12-week multicenter randomized controlled open-label trial for evaluating the hypoglycemic effect of henagliflozin followed by a 24-week extension period.",[27,456,457],"Weight Loss","Pre-diabetes",[459,27,460,461],"Henagliflozin","Weight loss","Glucose","2024-01-11",{"date":464,"type":41},"2024-01-22",{"date":466,"type":21},"2024-02-15",{"date":468,"type":21},"2026-10-01",{"name":470,"class":81},"The First People's Hospital of Changzhou"]